• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic takes another crack at renal denervation

Medtronic takes another crack at renal denervation

April 1, 2015 By Brad Perriello

Medtronic takes another crack at renal denervation

Medtronic (NYSE:MDT) today said it’s taking another crack at renal denervation as a treatment for hypertension with the launch of a clinical program to examine the "confounding factors" that contributed to the high-profile failure of a prior trial.

Back in January 2014, Fridley, Minn.-based Medtronic shocked medtech when it announced that the highly anticipated Symplicity-3 trial failed to meet its efficacy endpoint. The company suspend enrollment in its other Symplicity trials around the world and later took a $200 million writedown on its renal denervation assets.

News of the trials failure reverberated throughout the medical device industry, prompting other companies to follow suit by either scaling back their RDN programs or spiking them altogether.

Today Medtronic said it won an investigational device exemption from the FDA for its global Spyral HTN program, beginning with a pair of studies using the next generation of its Symplicity line, the Symplicity Spyral catheter and Symplicity G3 radiofrequency generator. CFO Gary Ellis said in February that the company planned to submit for IDE approval from the FDA, but declined to go into detail on Medtronic’s new RDN program.

The 2 new trials, Spyral HTN-Off Med and Spyral HTN-On Med, are designed to examine RDN with and without high blood pressure medication. Unlike the Symplicity-3 trial and its cohort of severe, treatment-resistant high blood pressure, each 100-patient trial is slated to enroll subjects with moderate- to high-risk hypertension, Medtronic said.

Spyral Off-Med aims to isolate the effect of RDN on high blood pressure. Spyral On-Med is designed to evaluate the treatment with the use of anti-hypertensive medications, but not at the maximum doses required by Symplicity-3’s protocol. Patient compliance with the medication regimen will also be closely monitored and patients will be tracked using ambulatory blood pressure measurements, according to the company.

Depending on the studies’ outcomes, Medtronic said it will consider a pivotal trial ahead of bids for pre-market approval in the U.S. and Shonin approval in Japan.

"Medtronic believes the underlying science behind renal denervation is strong and that there is a clear, unmet need for people with uncontrolled hypertension. Therefore, we remain committed to exploring the clinical potential of renal denervation in this population," coronary & renal denervation general manager Jason Weidman said in prepared remarks. "To get to this point, we’ve performed extensive analyses and conducted additional pre-clinical testing following the Symplicity HTN-3 trial. We’ve also consulted with the FDA and reimbursement bodies, and partnered with renowned thought-leaders worldwide to develop this novel clinical trial protocol."

Filed Under: News Well Tagged With: Clinical Trials, Hypertension, Renal

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy